CLEC9A

CLEC9A encodes C-type lectin domain family 9 member A, commonly known as DNGR-1. Expressed primarily on conventional dendritic cells (cDC1s), it acts as a pattern recognition receptor binding to exposed F-actin from necrotic cells. This interaction activates Syk-CARD9 signaling, driving cross-presentation of dead cell-derived antigens to CD8+ T cells—critical for adaptive immunity against pathogens and tumors.
Dysregulation of CLEC9A links to autoimmune disorders like systemic lupus erythematosus, where excessive cross-presentation may trigger self-reactive T cells. In oncology, targeting CLEC9A to enhance cDC1 function is promising; preclinical studies use agonistic antibodies to boost anti-tumor immunity, with early-phase clinical trials underway to validate efficacy.